This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
SMAD9 / SMAD family member 9 · IHC design guide
Design Immunohistochemistry for SMAD9
Plan chromogenic SMAD9 IHC in paraffin sections using the catalog antibody (datasheet A04932). Choose tissue controls and interpret cytoplasmic and nuclear staining using the tissue profile, while accounting for its low consistency with RNA expression (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
SMAD9 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic and nuclear staining (HPA tissue IHC) | |
| Staining pattern | Glandular and epithelial cells stain; cytoplasm and nuclei (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, heat-mediated (datasheet A04932) | |
| Positive control | Appendix+4 more · see all | |
| Negative control | Adipose tissue+1 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation conditions consistent across sections. (standard IHC practice; not target-specific) | |
| Caveat | Antibody staining has low consistency with RNA expression (HPA tissue IHC) | |
| Regulation | SMAD4 binding may shift nuclear signal (UniProt; by similarity) | |
| Isoform / epitope | 2 isoforms (A and B); epitope differences unspecified (UniProt) |
Section 1
Recommended SMAD9 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is supplemented by two published SMAD9 chromogenic IHC protocols (PMC7923649; PMC10685465).
| Sample | Paraffin-embedded human liver cancer tissue; fixative not specified (datasheet A04932) |
| Fixation | Image fixative and duration unreported (datasheet A04932); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: Citrate pH 6.0 (datasheet A04932); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-SMAD9, 1:50-1:200 (datasheet A04932) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | SMAD9-positive staining in glandular cells of appendix (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic and nuclear expression in several tissues. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated citrate retrieval at pH 6.0 (datasheet A04932); one published protocol also uses citrate buffer (PMC10685465).
Section 2
What Is the Expected SMAD9 Staining Pattern?
SMAD9 staining may appear in the cytoplasm and nucleus of epithelial and glandular cells in paraffin tissue sections (HPA: tissue IHC profile). Several such cell populations show High staining, including colonic glandular and bronchial respiratory epithelial cells (HPA: tissue IHC). SMAD9 has no transmembrane segment (UniProt O15198: topology). Interpret the pattern cautiously: HPA rates its IHC data Approved but reports low consistency between antibody staining and RNA expression (HPA: reliability description).
| Cytoplasmic and nuclear staining in colonic glandular cells or bronchial respiratory epithelial cells. | This fits the reported tissue pattern and High staining in those cells (HPA: tissue IHC). Score each compartment and cell population separately; nuclear staining alone does not establish pathway activation (UniProt O15198: ligand-dependent localization, by similarity). |
| A predominantly plasma-membrane outline, with little cellular staining. | This conflicts with the reported cytoplasmic and nuclear distribution and absence of a transmembrane segment (HPA: tissue IHC; UniProt O15198: topology). Review morphology and controls before assigning the outline to SMAD9 (general IHC practice). |
| Strong signal in adipocytes or cells of the cerebellar granular layer. | Both populations are reported as Not detected (HPA: tissue IHC). Unexpected signal could reflect cross-reactivity or endogenous detection activity; check controls before treating either population as positive (general IHC practice). |
| Chromogen spread across tissue, including spaces between cells. | A widespread deposit lacks the compartment and cell-type pattern reported for SMAD9 (HPA: tissue IHC). Uneven reagent coverage, inadequate washing, or endogenous detection activity are general IHC possibilities (general IHC practice). |
| No cellular signal in an otherwise interpretable colon or bronchus section. | These contain cell populations reported as High (HPA: tissue IHC). Check section quality, retrieval, antibody application, and detection controls before concluding absence of SMAD9 (general IHC practice). |
💡Expected SMAD9 appearanceA credible positive is discernible cytoplasmic and/or nuclear staining in the relevant epithelial or glandular cells, potentially High in the listed examples; a dominant membrane rim or widespread acellular deposit is suspect (HPA: tissue IHC; UniProt O15198: topology; general IHC practice).
| Cell population and tissue context | HPA reports High staining in several glandular and epithelial populations, but Not detected in adipocytes and cerebellar granular-layer cells (HPA: tissue IHC). Compare like cell populations rather than scoring an entire section uniformly (general IHC practice). |
| Conditional compartment distribution | UniProt places SMAD9 in the cytoplasm without ligand and describes migration to the nucleus with SMAD4 by similarity (UniProt O15198: subcellular location). Compartment balance can vary; a static stain cannot establish why SMAD9 is nuclear (general IHC interpretation). |
| Antibody evidence | Two listed antibodies have Approved IHC status, while HPA notes low consistency between staining and RNA expression (HPA: antibody validation; tissue reliability). Treat an unexpected cell pattern as needing control-based review rather than assuming it represents SMAD9 (general IHC practice). |
| Isoforms and epitope coverage | UniProt lists 2 isoforms, A and B (UniProt O15198: isoforms). The supplied evidence does not locate the catalog antibody's epitope or establish isoform-specific IHC staining, so do not assign an observed compartment or cell pattern to one isoform. |
| IF evidence and transfer to sections | HPA reports mainly nucleoplasmic, with additional cytosolic, localization in ICC-IF (HPA: subcellular). That observation helps assess compartments but does not set an IHC intensity threshold in paraffin sections (HPA: tissue IHC; general IHC interpretation). |
| Situation | Likely cause | Next action |
|---|---|---|
| Expected glandular or respiratory epithelial staining is absent. | The section may have a detection or preparation problem; these populations are reported as High (HPA: tissue IHC; general IHC practice). | Confirm tissue morphology and run the catalog antibody's IHC-P procedure with its specified retrieval and detection controls; compare a known-positive section in the same run (general IHC practice). |
| Adipocytes or cerebellar granular-layer cells stain strongly. | That conflicts with their Not detected HPA observations; cross-reactivity or endogenous activity is possible (HPA: tissue IHC; general IHC practice). | Review a reagent control and the cell morphology; for chromogenic detection, check the relevant endogenous-enzyme blocking control before scoring the cells (general IHC practice). |
| The slide has diffuse chromogen or poor cellular contrast. | Background can arise from detection reagents, inadequate washing, or uneven reagent handling (general IHC practice). | Check a control lacking primary antibody, washing, and reagent coverage; interpret only localized cellular signal against the expected tissue pattern (general IHC practice; HPA: tissue IHC). |
| A membrane rim dominates while cytoplasm and nuclei are faint. | The rim is discordant with SMAD9's cytoplasmic and nuclear locations and lack of a transmembrane segment (HPA: tissue IHC; UniProt O15198: topology). | Check whether the rim follows tissue edges or nonspecific deposits, then assess controls and a morphologically intact area before assigning localization (general IHC practice). |
| Nuclear staining varies among cells in one section. | SMAD9 can occur in both compartments, with nuclear migration described in a SMAD4 complex by similarity (UniProt O15198: subcellular location). Variation alone does not identify the underlying signaling state. | Record nuclear and cytoplasmic staining separately by cell type and compare with controls; avoid calling BMP activation from a single static section (general IHC interpretation; UniProt O15198: function). |
| Why does ICC-IF look more nuclear than the paraffin-section IHC? | HPA describes mainly nucleoplasmic ICC-IF staining, while its tissue IHC profile includes cytoplasmic and nuclear expression (HPA: subcellular; tissue IHC). The supplied evidence does not establish why the preparations differ. | Interpret each assay against its own reported pattern and controls; do not use ICC-IF intensity as an IHC scoring cutoff (HPA: subcellular; tissue IHC; general IHC interpretation). |
Experiment evidence
IHC & IF images showing SMAD9 staining
A04932 · IHCImmunohistochemistry of paraffin-embedded human liver cancer using Smad9 Rabbit pAb at dilution of 1:100 .Perform high pressure antigen retr
A04932 · IHCImmunohistochemistry of paraffin-embedded human placenta using Smad9 Rabbit pAb at dilution of 1:100 .Perform high pressure antigen retrieva
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000120693-SMAD9/tissue/cerebral+cortex#imid_3023208
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000120693-SMAD9/tissue/colon#imid_3023150
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000120693-SMAD9/tissue/liver#imid_3023143
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000120693-SMAD9/tissue/kidney#imid_3023152
HPA · ICC-IF HEK293Human Protein Atlas immunofluorescence, HEK293, antibody HPA031162; green = SMAD9, blue = nucleus, red = microtubules.
HPA · ICC-IF HEK293Human Protein Atlas immunofluorescence, HEK293, antibody HPA031162; green = SMAD9, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for SMAD9 IHC & IF
🧪Run appendix first: its glandular cells should stain (HPA: High in appendix glandular cells). Use adipose tissue as the negative tissue (HPA: Not detected in adipocytes); on the appendix slide, assess background in adjacent cells that remain unstained, without assuming those cells are biologically SMAD9-negative.
Positive control tissue: Appendix (Glandular cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show SMAD9 in HEK293, Rh30, U2OS, hTERT-RPE1 (serum starved), with annotated localisation: Nucleoplasm (enhanced) (HPA subcellular).
Technical controls: Include a no-primary (secondary-only) control, concentration-matched normal rabbit IgG for the rabbit polyclonal catalog antibody (selected-SKU caption: Rabbit pAb), and SMAD9-knockout tissue or a validated peptide-block control if available. Block endogenous peroxidase and check inflammatory cells in appendix for background signal (standard chromogenic IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported in the supplied evidence, and the selected-SKU paraffin-section caption does not state a fixative. That caption uses high-pressure retrieval in 10 mM citrate at pH 6.0 before staining at 1:100 (selected-SKU tissue-IHC caption); it does not establish whether retrieval is required under other conditions. The evidence does not establish whether frozen sections or IF are easier; ICC-IF images exist for this target (HPA: subcellular), while inflammatory cells in appendix warrant a check for endogenous peroxidase background (standard IHC practice).
HPA tissue IHC evidence for SMAD9
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Low consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Breast | Glandular cells | High | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | High | Protein (IHC) | HPA → |
| Cervix | Squamous epithelial cells | High | Protein (IHC) | HPA → |
| Colon | Glandular cells | High | Protein (IHC) | HPA → |
Section 3
Advanced SMAD9 IHC Tips
Use compartment-aware scoring and matched controls when troubleshooting SMAD9 staining in paraffin sections (UniProt O15198 localisation; standard IHC practice).
Which retrieval condition should I start with for paraffin-section SMAD9 IHC?
Start with heat-mediated retrieval in 10 mM citrate buffer at pH 6.0 for paraffin-section SMAD9 IHC (datasheet A04932). The selected image used high-pressure retrieval before staining human liver cancer at 1:100, but its caption does not report a fixative (selected-SKU tissue-IHC caption). Keep heating and cooling conditions consistent across sections, then inspect nuclear and cytoplasmic staining in morphologically comparable cells; both compartments are plausible for SMAD9 (UniProt O15198 localisation; standard IHC practice). If signal is weak, compare retrieval durations on matched sections before testing another buffer, retaining the citrate condition as the reference (standard IHC practice).
How should I investigate weak SMAD9 staining when fixation records vary?
Target-specific sensitivity to fixation is unknown: the selected paraffin-section caption reports retrieval but no fixative, and no SMAD9 fixation comparison is supplied (selected-SKU tissue-IHC caption). Record the fixative, time before fixation, and fixation duration for each specimen, then compare sections with similar processing histories (standard IHC practice). If you can prepare controlled material, test 6 and 24 hours of fixation as experimental conditions while holding retrieval and detection constant; neither duration is established as optimal for SMAD9 (standard IHC practice). Interpret any difference alongside morphology and background, because variable processing can affect apparent staining independently of SMAD9 abundance (standard IHC practice).
Should SMAD9 staining be nuclear, cytoplasmic, or both?
Score nuclear and cytoplasmic staining separately: SMAD9 is reported in the cytoplasm and nucleus, with nuclear migration when complexed with SMAD4 described by similarity (UniProt O15198 localisation). The HPA tissue profile also reports both compartments, while its subcellular data emphasize nucleoplasm with additional cytosol (HPA tissue IHC; HPA subcellular). Use a nuclear counterstain and clear cell boundaries to distinguish nuclear signal from cytoplasm overlying a nucleus (standard IHC practice). A shift in the nuclear fraction can support a localisation change, but total chromogenic intensity alone cannot establish BMP pathway activation (UniProt O15198 function and localisation; standard IHC interpretation).
How can I assess whether the antibody detects both SMAD9 isoforms?
SMAD9 has 2 listed isoforms, A and B, and the record places MH1 at residues 16–140 and MH2 at 273–467 (UniProt O15198 isoforms and domains). The supplied evidence does not map the catalog antibody’s epitope, so staining cannot establish which isoform it recognizes (supplied antibody evidence). Obtain an epitope map before making an isoform-specific claim, and check whether that sequence is present in each isoform (standard antibody-validation practice). If that map is unavailable, compare staining with an independently validated antibody or an orthogonal expression assay, while reporting the result as SMAD9 immunoreactivity (standard IHC practice).
How should I adapt the localisation check to multiplex SMAD9 IF?
For IF/ICC, pair SMAD9 with an epithelial marker when examining glandular cells, since high glandular-cell staining is reported in several tissues (HPA tissue IHC; standard multiplex IF practice). Choose a far-red channel for the weaker signal when tissue autofluorescence interferes with shorter wavelengths, and include single-channel controls to assess bleed-through (standard IF practice). SMAD9 has no transmembrane segment and is reported in cytoplasm and nucleus, so permeabilise cells for an intracellular epitope; verify access against background rather than assuming the antibody’s epitope location (UniProt O15198 topology and localisation; standard IF practice). Compare nuclear and cytosolic signal against the counterstain and cell marker within the same cells (HPA subcellular; standard IF practice).
What should I check when SMAD9 chromogenic staining looks diffuse?
First compare the section with a no-primary control and inspect blank regions, tissue edges, and damaged areas for deposit unrelated to cellular morphology (standard IHC practice). Include a peroxidase block before chromogenic detection and assess whether the blocking step reduces nonspecific DAB signal (standard chromogenic IHC practice). Titrate the catalog antibody around its documented 1:100 tissue-image dilution only as an optimization experiment, keeping retrieval and detection conditions fixed; that dilution comes from one paraffin-section image (selected-SKU tissue-IHC caption; standard IHC practice). Preserve compartment information when judging improvement, because credible SMAD9 staining may occupy nuclei and cytoplasm (UniProt O15198 localisation; HPA tissue IHC).
How should I quantify SMAD9 staining across differently composed sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and viable tissue area before scoring, then record nuclear and cytoplasmic SMAD9 separately because both locations are reported (UniProt O15198 localisation; standard IHC practice). For nuclear staining, use an H-score from 0–300, combining the percentage of cells at intensity grades 0–3; record the percentage positive as a companion measure (standard IHC scoring practice). For a sparse positive population, report positive-cell density per mm² of viable tissue as well (standard IHC scoring practice). Normalize each result to the eligible cells or viable area actually assessed, and keep threshold, counterstain, and imaging settings consistent across cases (standard IHC practice).
How can I distinguish credible SMAD9 positivity from staining artefact?
Credible staining should follow identifiable cells and a plausible nuclear or cytoplasmic compartment; those locations agree with SMAD9 localisation evidence (UniProt O15198 localisation; HPA tissue IHC). Compare candidate positive cells with reported patterns: glandular cells in appendix and colon show high staining, whereas adipocytes are reported as not detected (HPA tissue IHC). Discount signal concentrated at cut edges, necrotic regions, or areas positive in the no-primary control, and investigate persistent chromogen after peroxidase blocking (standard IHC practice). Treat a positive result cautiously because HPA rates its tissue staining approved while reporting low consistency with RNA expression (HPA tissue IHC).
Boster reagents
Best SMAD9 / SMAD family member 9 IHC Antibodies
The catalog antibody has real IHC images from paraffin-embedded human liver cancer and placenta; IF/ICC is listed for human, mouse and rat samples (A04932 catalog; A04932 IHC captions).
Real IHC data
Anti-SMAD9 Antibody
Cat # A04932
A04932 is the sole card and shows IHC staining of paraffin-embedded human liver cancer and placenta at 1:100 after citrate retrieval (A04932 IHC captions). IF/ICC is listed, with human, mouse and rat reactivity, but no IF image is supplied (A04932 catalog).
Which to pick: Choose A04932 for paraffin-section IHC: its own captions document human liver cancer and placenta staining, while the fixative is unreported (A04932 IHC captions). A04932 is also the listed IF/ICC and cross-species option because its applications include IF/ICC and its stated reactivity covers human, mouse and rat; the supplied images demonstrate IHC in human tissue only (A04932 catalog; A04932 IHC captions). It is a rabbit polyclonal antibody (A04932 IHC captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry O15198 (SMAD9_HUMAN, SMAD family member 9).
- Human Protein Atlas. SMAD9 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. SMAD9 subcellular location (ICC-IF): Mainly localized to the nucleoplasm. In addition localized to the cytosol..
- Human Protein Atlas. SMAD9 antibody validation summary (2 antibodies).
- Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma. BMC cancer 2021 — PMC7923649.
- Long noncoding RNA KCNMA1-AS1 promotes osteogenic differentiation of human bone marrow mesenchymal stem cells by activating the SMAD9 signaling pathway. Biology direct 2023 — PMC10685465.
- SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma. Journal of experimental & clinical cancer research : CR 2022 — PMC9764568.
- Pharmacological Manipulation of Early Zebrafish Skeletal Development Shows an Important Role for Smad9 in Control of Skeletal Progenitor Populations. Biomolecules 2021 — PMC7918065.
- PubMed PMID:9205116 — UniProt-cited evidence.
- PubMed PMID:15057823 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for SMAD9 (SMAD family member 9). Expected localisation Cytoplasmic and nuclear staining (HPA tissue IHC). Antigen retrieval: Citrate pH 6.0 HIER, heat-mediated (datasheet A04932). Validated IHC antibody: A04932 at 1:50-1:200 (the product's own IHC validation image is shown). Controls (HPA): positive Appendix (Glandular cells); negative Adipose tissue. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Paraffin-embedded human liver cancer tissue; fixative not specified (datasheet A04932); 2. Fixation: Image fixative and duration unreported (datasheet A04932); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: Citrate pH 6.0 (datasheet A04932); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-SMAD9, 1:50-1:200 (datasheet A04932); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation conditions consistent across sections. (standard IHC practice; not target-specific); Caveat: Antibody staining has low consistency with RNA expression (HPA tissue IHC); Isoform / epitope: 2 isoforms (A and B); epitope differences unspecified (UniProt); Regulation: SMAD4 binding may shift nuclear signal (UniProt; by similarity). Evidence: UniProt O15198, HPA tissue IHC · Approved, HPA ICC-IF · Mainly localized to the nucleoplasm. In addition localized to the…, Datasheet A04932, PMC7923649, PMC10685465. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/SMAD9/immunohistochemistry-ihc-guide.